Bausch Health, Canada Receives a Positive Recommendation from the CADTH Canadian Drug Expert Committee (CDEC) for DUOBRII™ - a Novel Topical Antipsoriatic Prescription Drug

• DUOBRII is a topical antipsoriatic medication introduced in Canada¹
• Positive CADTH recommendation moves DUOBRII closer to federal, provincial and territorial drug plan reimbursement
• DUOBRII provides the combined action of two compounds, halobetasol propionate, a corticosteroid, and tazarotene, a retinoid prodrug¹
• Formulated with PRISMATREX™, a proprietary technology, DUOBRII lotion improves the signs and symptoms of plaque psoriasis in adult patients with moderate to severe plaque psoriasis¹
• DUOBRII is manufactured for distribution throughout Canada and the United States at the Company's Quebec manufacturing facility in Laval

LAVAL, QC, Nov. 10, 2020 /CNW Telbec/ - Bausch Health, Canada, part of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), ("Bausch Health" or the "Company") today announced that the CADTH Canadian Drug Expert Committee (CDEC) issued a positive recommendation for DUOBRII™ (0.01% w/w halobetasol propionate and 0.045% w/w tazarotene), a combination product composed of a corticosteroid and a retinoid prodrug.¹

Bausch Health corporate video featuring Duobrii manufacturing in Canada.

According to the CDEC recommendation, halobetasol propionate and tazarotene should be reimbursed for improving the signs and symptoms of plaque psoriasis in adult patients with moderate-to-severe plaque psoriasis, if specific conditions are met.²

"As a company committed to the Canadian psoriasis community, we are sensitive to the challenges of patients and physicians seeking to improve quality of life and achieve clear skin. We are excited about the CDEC positive recommendation that moves DUOBRII closer to federal, provincial and territorial reimbursement, and we are very proud that DUOBRII is manufactured at our own facility here in Canada," said Richard Lajoie, president and general manager, Bausch Health, Canada.

DUOBRII is already reimbursed by the majority of private insurance plans in Canada.

DUOBRII lotion provides a novel combination action of two well-known ingredients having long-established efficacy profiles. When administered together in DUOBRII, they provide complementary effects due to their individual modes of action targeting different receptors and pathways to achieve anti-inflammatory control and epidermal morphologic restoration.¹

DUOBRII is also unique based on its PRISMATREX™ technology, a polymeric emulsification system that provides a stable condition in which emulsion droplets retain their distribution across time and temperature.³  

About Bausch Health Companies Inc. 

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. In Canada, the Company's prescription product portfolio is focused on eye health, dermatology and cardio-metabolic conditions. More information can be found on the Company's website at bauschhealth.ca.

¹ DUOBRII Product Monograph. Bausch Health, Canada Inc. June 8, 2020

² DUOBRII (halobetasol propionate and tazarotene lotion) CADTH Canadian Drug Expert Committee Recommendation – Final: https://www.cadth.ca/sites/default/files/cdr/complete/SR0638%20Duobrii%20-%20CDEC%20Final%20Recommendation%20October%2030%2C%202020_For%20Posting.pdf. Accessed November 2020.

³ Data on file. Bausch Health, Canada Inc.

SOURCE Bausch Health

Investor Contact: Arthur Shannon, [email protected], [phone], [phone] (toll free); Media Contact: Lainie Keller, [email protected], [phone]

Related Links

https://www.bauschhealth.ca/